Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.

Xinhui Chen,Nicolas Isambert, Rafael López-López,Monica Giovannini,Nathalie Pognan,Shruti Kapoor,Michelle Quinlan,Benoit You,Xiaoming Cui,Gholamreza Rahmanzadeh,Morten Mau-Sorensen

British journal of clinical pharmacology（2023）

引用 0|浏览17

暂无评分

摘要

The data from this study demonstrated that capmatinib is a moderate CYP1A2 inhibitor. Capmatinib administration did not cause any clinically relevant changes in midazolam exposure.

查看译文

关键词

CYP1A2,CYP3A,DDI,caffeine,capmatinib,midazolam

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要